- Home
- FBRX vs INCR Comparison
FBRX vs INCR Comparison
Compare FBRX & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- INCR
- Stock Information
- Founded
- FBRX N/A
- INCR 1994
- Country
- FBRX United States
- INCR Israel
- Employees
- FBRX N/A
- INCR N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- INCR Health Care
- Exchange
- FBRX Nasdaq
- INCR Nasdaq
- Market Cap
- FBRX 84.0M
- INCR 84.5M
- IPO Year
- FBRX N/A
- INCR N/A
- Fundamental
- Price
- FBRX $11.80
- INCR $1.46
- Analyst Decision
- FBRX Strong Buy
- INCR
- Analyst Count
- FBRX 2
- INCR 0
- Target Price
- FBRX $61.00
- INCR N/A
- AVG Volume (30 Days)
- FBRX 164.2K
- INCR 11.6K
- Earning Date
- FBRX 08-13-2025
- INCR 08-15-2025
- Dividend Yield
- FBRX N/A
- INCR N/A
- EPS Growth
- FBRX N/A
- INCR N/A
- EPS
- FBRX N/A
- INCR N/A
- Revenue
- FBRX N/A
- INCR $65,575,323.00
- Revenue This Year
- FBRX N/A
- INCR $69.54
- Revenue Next Year
- FBRX N/A
- INCR $41.75
- P/E Ratio
- FBRX N/A
- INCR N/A
- Revenue Growth
- FBRX N/A
- INCR N/A
- 52 Week Low
- FBRX $4.11
- INCR $1.17
- 52 Week High
- FBRX $28.68
- INCR $2.62
- Technical
- Relative Strength Index (RSI)
- FBRX 54.37
- INCR 46.71
- Support Level
- FBRX $10.15
- INCR $1.43
- Resistance Level
- FBRX $19.63
- INCR $1.56
- Average True Range (ATR)
- FBRX 1.84
- INCR 0.06
- MACD
- FBRX -0.22
- INCR -0.00
- Stochastic Oscillator
- FBRX 22.15
- INCR 46.15
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.